Drug Trial Radar · NCT04655911
A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101
Last checked: Nov 19, 2026Latest source record: May 31, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1
Actual
Start
Oct 28, 2020
Primary completion
Apr 7, 2022
Study completion Apr 7, 2022
Sponsor
- Lead sponsor
- Abeona Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Dec 7, 2020
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, non-interventional, long-term follow-up (LTFU) study in participants who have been treated with ABO-101 in a prior trial. Eligible participants will undergo clinical evaluations at prespecified intervals for 3 years from the last visit in the prior clinical trial (up to 5 years post-treatment).
Conditions
- Mucopolysaccharidosis III-B
Interventions
ABO-101Biological
Gene therapy rAAV9.CMV.hNAGLU
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: 60 months
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
Nationwide Children's Hospital
Columbus, Ohio
Armand-Trousseau Hospital
Paris, France
University Hospital Hamburg-Eppendorf
Hamburg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.